. Author manuscript; available in PMC: 2020 Nov 1.

Published in final edited form as: Eur Urol Oncol. 2019 Jun 14;2(6):605–616. doi: 10.1016/j.euo.2019.05.004

Table 4 −.

Pooled estimate detection rates of the MRI-stratified pathway and the systematic TRUS-guided pathway, and corresponding relative detection rates for clinically significant, clinically insignificant, and any prostate cancer

	csPCa			cisPCa			Any PCa
	Detection rate (95% CI)	p value^a	I² (%)	Detection rate (95% CI)	p value^a	I² (%)	Detection rate (95% CI)	p value^a	I² (%)
MRI-stratified pathway	0.36 (0.23–0.53)	<0.01	97	0.10 (0.04–0.19)	0.09	94	0.50 (0.40–0.62)	<0.01	94
Systematic TRUS-guided biopsy pathway	0.25 (0.18–0.33)	<0.01	90	0.10 (0.05–0.17)	<0.01	91	0.38 (0.30–0.46)	<0.01	87
Relative detection rate	1.45 (1.09–1.92)	<0.01	82	0.99 (0.61–1.60)	<0.01	72	1.35 (1.05–1.73)	<0.01	88

CI = confidence interval; cisPCa = clinically insignificant prostate cancer; csPCa = clinically significant prostate cancer; MRI = magnetic resonance imaging; PCa = prostate cancer; TRUS = transrectal ultrasound.

p value for the Q test.